Magnesium and lidocaine composition

Abstract

Embodiments include a method of treating mania comprising administering to a patient at least one dose of a composition comprising magnesium and lidocaine; determining whether the patient exhibits a warm sensation after administering at least one dose of the composition; under the condition that the patient shows the warm feeling, waiting for the patient shows that the warm feeling disappears; and verifying whether mania has decreased to a predetermined level after the patient indicates that the warm sensation has disappeared.

Description

BACKGROUND

[0001] The present invention relates generally to a composition comprising magnesium and lidocaine. In particular, embodiments of the present invention are directed to a method of delivering a composition comprising magnesium and lidocaine for the treatment of pain, acute psychosis, and mania. SUMMARY

[0002] In one aspect of the present invention, a method of treating mania includes administering to a patient a bolus of at least one dose of a composition comprising magnesium and lidocaine; determining whether the patient exhibits a sensation of warmth after the bolus of the at least one dose of the composition is administered; waiting for the patient to indicate that the sensation of warmth has dissipated if the patient exhibits the sensation of warmth; and verifying that the mania is reduced to a predetermined level after waiting for the patient to indicate that the sensation of warmth has dissipated.

[0003] In other aspects of the present invention, a method of treating pain includes administering to a patient a bolus of at least one dose of a composition comprising magnesium and lidocaine; determining whether the patient exhibits a sensation of warmth after the bolus of the at least one dose of the composition is administered; waiting for the patient to indicate that the sensation of warmth has dissipated if the patient exhibits the sensation of warmth; and verifying that the pain is reduced to a predetermined level after waiting for the patient to indicate that the sensation of warmth has dissipated.

[0004] In another aspect of the present invention, a method of treating pain includes infusing a patient with a dose of a composition comprising magnesium and lidocaine; determining whether the patient has a central nervous system (CNS) symptom based on the infused dose of the composition; waiting for the CNS symptom to subside based on the infused dose of the composition if the patient has the CNS symptom; and verifying that the pain is reduced to a predetermined level based on the infused dose of the composition after the patient does not have the CNS symptom.

[0005] In another aspect of the present invention, a method of treating mania includes infusing a patient with a dose of a composition comprising magnesium and lidocaine; determining whether the patient has a central nervous system (CNS) symptom based on the infused dose of the composition; waiting for the CNS symptom to subside based on the infused dose of the composition if the patient has the CNS symptom; and verifying that the mania is reduced to a predetermined level based on the infused dose of the composition after the patient does not have the CNS symptom. BRIEF DESCRIPTION OF DRAWINGS

[0006] In the following detailed description, the application is described by way of non-limiting examples of illustrative embodiments of the present invention with reference to the drawings described below.

[0007] Figure 1 A flowchart showing the administration of a first composition comprising magnesium and lidocaine for pain is shown in accordance with aspects of the present invention.

[0008] Figure 2 Another flow chart showing administration of a first composition comprising magnesium and lidocaine for pain according to aspects of the present application is shown.

[0009] Figure 3 Another flow chart showing administration of a first composition comprising magnesium and lidocaine for acute psychosis and mania according to aspects of the present application is shown.

[0010] Figure 4 Another flow chart showing administration of a first composition comprising magnesium and lidocaine for acute psychosis and mania according to aspects of the present application is shown.

[0011] Figure 5 Another flow chart showing administration of a second composition comprising magnesium and lidocaine for acute psychosis and mania according to aspects of the present application is shown.

[0012] Figure 6 Another flow chart showing administration of a second composition comprising magnesium and lidocaine for pain according to aspects of the present application is shown.

[0013] Figure 7 A table showing compositions for addressing pain management according to aspects of the present application is shown.

[0014] Figure 8 A table showing compositions for treating acute psychosis and mania according to aspects of the present application is shown. DETAILED DESCRIPTION

[0015] The present application generally relates to a composition comprising magnesium and lidocaine. Specifically, embodiments of the present application specifically relate to a method for treating pain and acute psychosis and mania, delivering a composition comprising magnesium and lidocaine. In one example, mania can include loss of appetite, poor sleep, pressured speech, and manic episodes.

[0016] When spinal cord neurons are subjected to repeated or high intensity noxious stimuli, the spinal cord neurons gradually become more and more excitable even after the stimulus is removed. This condition is known as central sensitization or wind-up phenomenon, leading to unresponsiveness or chronic intractable pain that is resistant to potent analgesics. In addition, similar cellular responses also play a role in psychiatric disorders such as acute psychosis and mania.

[0017] In embodiments of the invention, compositions comprising magnesium and lidocaine reverse the hyperactivity by placing magnesium intracellularly and allowing it to bind to receptor sites. However, simply taking magnesium does not reverse the hyperactivity, treat pain, or treat acute psychosis and mania. Furthermore, lidocaine alone does not treat chronic intractable pain, acute psychosis, or mania. In this invention, compositions comprising magnesium and lidocaine are key to the effective treatment of pain, acute psychosis, and mania.

[0018] According to an aspect of the present invention, a first composition for treating pain, acute psychosis, and mania is provided, comprising:

[0019] 1) 2 mg magnesium in water; and

[0020] 2) 200mg of preservative-free 2% lidocaine.

[0021] In an embodiment of the invention, the first composition is administered in four bolus doses. In a further embodiment of the invention, administering the first composition in four bolus doses produces high plasma levels. In one aspect of the invention, a warming sensation is produced in the patient when the first composition is administered in four bolus doses. During the administration of the first composition by bolus injection, the patient reports any symptoms of warming sensation or lidocaine toxicity (e.g., metallic taste, tinnitus, etc.) and indicates when the warming sensation or lidocaine toxicity symptoms disappear. If the first composition is administered without waiting for the lidocaine toxicity symptoms to subside, the lidocaine in the first composition may cause seizures and cardiac arrest at toxic doses. Waiting for the warming sensation to subside at previous doses improves tolerance to warmth in subsequent bolus injections and eliminates the risk of lidocaine toxicity. Therefore, by administering the first composition in a first bolus dose, waiting for the patient to report the disappearance of the warming sensation, administering the second composition in a second bolus dose, waiting for the patient to report the disappearance of the warming sensation, administering the first composition in a third bolus dose, waiting for the patient to report the disappearance of the warming sensation, and administering the first composition in a fourth bolus dose, seizures and cardiac arrest in the patient can be avoided. In one example, the first composition is administered by dividing it into four equal parts for bolus injection (i.e., each syringe contains 1 / 4 of the total amount of the first composition) and injecting the patient with one syringe's worth of the composition at a time during each bolus injection. In a further embodiment, the first composition comprises 2 mg of magnesium and 200 mg of preservative-free 2% lidocaine in 50 mL of sterile water. In one example, severe pain can be reduced by up to 66% by administering the first composition.

[0022] In a further embodiment, by carefully managing and discussing with the patient central nervous system (CNS) symptoms and lidocaine toxicity as precursors to seizures and cardiac arrest, the first composition can be administered via bolus injection at fewer than four doses. Furthermore, in a further embodiment, the first composition can be administered via bolus injection at more than four doses to further improve safety and avoid seizures and cardiac arrest due to lidocaine toxicity.

[0023] In a further embodiment of the invention, during administration of the first composition by bolus injection, the patient reports whether they experience central nervous system symptoms, such as a metallic taste in the mouth or tinnitus. If the first composition is administered without knowing whether the patient has central nervous system symptoms (such as a metallic taste in the mouth), the lidocaine in the first composition may cause seizures and cardiac arrest at toxic doses. Therefore, by bolus injection of multiple doses (e.g., four doses) of the first composition, seizures and cardiac arrest due to central nervous system symptoms can be avoided.

[0024] According to an aspect of the present invention, a second composition for treating pain, acute psychosis, and mania is provided, comprising:

[0025] 1) 2 mg magnesium in water; and

[0026] 2) 100mg of preservative-free 2% lidocaine.

[0027] In an embodiment of the invention, the first composition is infused into the patient in a single syringe over ten minutes. In a further embodiment of the invention, the second composition is typically used when the patient is mentally impaired (e.g., schizophrenia, acute psychosis, mania, dementia, Alzheimer's disease, etc.) or has difficulty communicating sensations of warmth or central nervous system symptoms. Therefore, by infusing the second composition with a lower concentration of lidocaine over ten minutes, safety can be improved, avoiding seizures and cardiac arrest due to lidocaine toxicity. In a further embodiment, the second composition comprises 2 mg of magnesium and 100 mg of preservative-free 2% lidocaine in 50 mL of sterile water. By administering the second composition once daily in a single syringe for three days, the patient's appetite returns on the first day, the patient is able to sleep six to eight hours per night on the second day, and all manic symptoms disappear after three days.

[0028] In a further embodiment, the second composition can be infused over a period of more than ten minutes to further improve safety and avoid seizures and cardiac arrest due to lidocaine toxicity. In other embodiments, the second composition can be infused in less than ten minutes, provided that safety is maintained to avoid seizures and cardiac arrest due to lidocaine toxicity.

[0029] In embodiments of the invention, by administering the first or second composition to the patient, a nonsteroidal anti-inflammatory drug (NSAID), such as ketorolac, is not required. Although ketorolac is a potent analgesic, it (and other NSAIDs) can cause bleeding and kidney damage. However, in aspects of the invention, the first composition and the second composition achieve the same potent analgesic benefits as an NSAID without the risk of bleeding and kidney damage.

[0030] In aspects of the present invention, the first and second compositions can be administered to a patient using at least one drug delivery method, including intravenous, intramuscular, gel, subcutaneous, inhalation, intra-articular, transdermal patch, oral (e.g., liquid, tablet, etc.), sublingual, intrathecal, etc. However, embodiments of the present invention are not limited to the above-described drug delivery process, and other drug delivery methods can be used for the first and second compositions.

[0031] Figure 1 A flowchart illustrating the application of a first composition comprising magnesium and lidocaine for pain relief according to various aspects of the present invention is shown. In step 100, a first dose of the first composition, comprising magnesium and lidocaine, is administered to a patient with high pain levels by bolus injection. In step 105, during the bolus injection of the first dose of the first composition, the patient is asked if they feel warmth. In step 110, if the patient reports a warm sensation, a second dose is administered until the patient reports that the warm sensation has disappeared. Then, in step 115, the first composition is administered to the patient by bolus injection of the second dose of the first composition. In a further embodiment, in step 115, after the patient no longer feels warmth, the first composition is administered to the patient by bolus injection of the second dose of the first composition.

[0032] exist Figure 1 In a further embodiment, in step 120, during the administration of the second dose of the first composition, the patient is asked if they feel warmth. In step 125, if the patient exhibits a warming sensation, the patient does not receive the second dose until the patient indicates that the warming sensation has disappeared. Then, in step 130, the first composition is administered to the patient by injecting a third dose of the first composition. In a further embodiment, in step 130, after the patient no longer exhibits a warming sensation, the first composition is administered to the patient by administering a third dose of the first composition.

[0033] exist Figure 1In one aspect of the invention, during step 135, the patient is asked if they feel warmth while administering the third dose of the first composition. In step 140, if the patient reports a warm sensation, the patient receives a fourth dose after the warm sensation has subsided. Then, in step 145, the first composition is administered to the patient by administering a fourth dose of the first composition. In a further embodiment, in step 145, after the patient no longer reports feeling warmth, the first composition is administered by administering a fourth dose of the first composition. Finally, in step 150, the patient verifies that the pain has been reduced to a predetermined level due to the four doses of the first composition administered.

[0034] Figure 2 Another flowchart illustrates the administration of a first composition comprising magnesium and lidocaine for pain according to various aspects of the invention. In step 200, the first composition comprising magnesium and lidocaine is administered to a patient with high pain levels by bolus administration of a first dose of the first composition. In step 205, during the oral administration of the first dose of the first composition, the patient is asked if there are any signs of central nervous system symptoms (e.g., a metallic taste in the patient's mouth). In step 210, if the patient exhibits CNS symptoms, the patient indicates when the CNS symptoms have subsided, and the flowchart proceeds to step 215. In a further embodiment, after the patient no longer exhibits CNS symptoms in step 215, the first composition is administered to the patient by bolus administration of a second dose of the first composition.

[0035] exist Figure 2 In a further embodiment, in step 220, during the administration of the second dose of the first composition, the patient is asked if there are any signs of CNS symptoms. In step 225, if the patient exhibits CNS symptoms, the patient indicates when the CNS symptoms have disappeared, and then the flowchart proceeds to step 230. In a further embodiment, in step 230, after the patient no longer exhibits CNS symptoms, the first composition is administered to the patient by administering a third dose of the first composition.

[0036] exist Figure 2 In one aspect of the invention, in step 235, during the administration of the third dose of the first composition, the patient is asked if there are any signs of CNS symptoms. In step 240, if the patient exhibits CNS symptoms, the patient indicates when the CNS symptoms have disappeared, and the flowchart proceeds to step 245. In a further embodiment, after the patient no longer exhibits CNS symptoms in step 245, the first composition is administered to the patient by administering a fourth dose of the first composition. Finally, in step 250, the patient verifies that the pain has been reduced to a predetermined level due to the administration of four doses of the first composition.

[0037] Figure 3A flowchart illustrating the administration of a first composition comprising magnesium and lidocaine for acute psychosis and mania according to aspects of the present invention is shown. In step 300, the first composition comprising magnesium and lidocaine is administered to a patient with high pain levels by injecting a first dose of the first composition. In step 305, during the injection of the first dose of the first composition, the patient is asked if they feel warmth. In step 310, if the patient reports a feeling of warmth, a second dose is administered until the patient reports that the feeling of warmth has disappeared. Then, in step 315, the first composition is administered to the patient by injecting a second dose of the first composition. In a further embodiment, in step 315, after the patient no longer feels warmth, the first composition is administered to the patient by injecting a second dose of the first composition.

[0038] exist Figure 3 In a further embodiment, in step 320, during the administration of the second dose of the first composition, the patient is asked whether they feel warmth. In step 325, if the patient exhibits a warming sensation, the patient receives the second dose again until the patient reports that the warming sensation has disappeared. Then, in step 330, the first composition is administered to the patient by administering a third dose of the first composition. In a further embodiment, in step 330, after the patient no longer exhibits a warming sensation, the first composition is administered to the patient by administering a third dose of the first composition.

[0039] exist Figure 3 In one aspect of the invention, in step 335, during the third dose of the first composition, the patient is asked if they feel warm. In step 340, if the patient exhibits a warm sensation, the patient receives a fourth dose bolus until the patient reports that the warm sensation has disappeared. Then, in step 345, the first composition is administered to the patient by bolus administration of a fourth third dose of the first composition. In a further embodiment, in step 345, after the patient no longer exhibits a warm sensation, the first composition is administered to the patient by bolus administration of a fourth dose of the first composition. Finally, in step 350, the patient verifies that due to the four bolus administrations of the first composition, acute psychosis and mania have decreased to a predetermined level.

[0040] Figure 4Another flowchart illustrating the administration of a first composition comprising magnesium and lidocaine for acute psychosis and mania according to aspects of the present invention is shown. In step 400, the first composition comprising magnesium and lidocaine is administered to a patient with high pain levels by bolus administration of a first dose of the first composition. In step 405, during oral administration of the first dose of the first composition, the patient is asked if there are any signs of central nervous system symptoms (e.g., a metallic taste in the patient's mouth). In step 410, if the patient exhibits CNS symptoms, the patient indicates when the CNS symptoms have subsided, and the flowchart proceeds to step 415. In a further embodiment, after the patient no longer exhibits CNS symptoms in step 415, the first composition is administered to the patient by bolus administration of a second dose of the first composition.

[0041] exist Figure 4 In a further embodiment, in step 420, during the administration of the second dose of the first composition, the patient is asked if there are any signs of CNS symptoms. In step 425, if the patient exhibits CNS symptoms, the patient indicates when the CNS symptoms have disappeared, and then the flowchart proceeds to step 430. In a further embodiment, in step 430, after the patient no longer exhibits CNS symptoms, the first composition is administered to the patient by administering a third dose of the first composition.

[0042] exist Figure 4 In one aspect of the invention, during step 435, while administering the third dose of the first composition, the patient is asked if there are any signs of CNS symptoms. In step 440, if the patient exhibits CNS symptoms, the patient indicates when the CNS symptoms have subsided, and the flowchart proceeds to step 445. In a further embodiment, after the patient no longer exhibits CNS symptoms in step 445, the first composition is administered to the patient using a fourth dose. Finally, in step 450, the patient verifies that due to the oral administration of the first composition at four doses, acute psychosis and mania have decreased to a predetermined level.

[0043] Figure 5Another flowchart illustrating the application of a second composition comprising magnesium and lidocaine for acute psychosis and mania according to aspects of the present invention is shown. In step 500, a patient suffering from acute psychosis and mania is administered the second composition comprising magnesium and lidocaine by bolus administration of a single dose of the second composition. In step 505, during the infusion of the single dose of the second composition, an electrocardiogram (EKG) machine is used to determine whether the patient exhibits abnormal arrhythmias or abnormal heartbeats. In step 510, if the patient exhibits abnormal arrhythmias or abnormal heartbeats, the flowchart proceeds to step 515 after the abnormal arrhythmias or abnormal heartbeats have disappeared. In a further embodiment, in step 515, it is verified whether the acute psychosis and mania have decreased to a predetermined level due to the single-dose infusion of the second composition. In a further embodiment, administration of the second composition comprising magnesium and lidocaine for acute psychosis and mania may further include determining whether the patient exhibits CNS symptoms (e.g., tinnitus in the ears, metallic taste in the mouth, etc.), waiting for the CNS symptoms to disappear, and verifying, based on the dose of the second composition infused, whether the acute psychosis or mania has decreased to a predetermined level due to the absence of CNS symptoms in the patient.

[0044] Figure 6 Another flowchart illustrating the administration of a second composition comprising magnesium and lidocaine for pain according to various aspects of the present invention is shown. In step 600, the second composition comprising magnesium and lidocaine is administered to a patient suffering from pain by infusing a single dose of the second composition to the patient. In step 605, during the infusion of the single dose of the second composition, an electrocardiogram (EKG) machine is used to determine whether the patient exhibits an abnormal arrhythmia or abnormal heartbeat. In step 610, if the patient exhibits an abnormal arrhythmia or abnormal heartbeat, the flowchart moves to step 615 after the abnormal arrhythmia or abnormal heartbeat has disappeared. In a further embodiment, in step 615, it is verified whether the pain has been reduced to a predetermined level due to the single-dose infusion of the second composition. In a further embodiment, the administration of the second composition comprising magnesium and lidocaine for pain may further include determining whether the patient exhibits CNS symptoms (e.g., tinnitus in the ear, metallic taste in the mouth, etc.), waiting for the CNS symptoms to disappear, and verifying whether the pain has been reduced to a predetermined level based on the infusion dose of the second composition after the patient no longer has CNS symptoms.

[0045] Figure 7A table of compositions for pain management according to various aspects of the present invention is shown. In embodiments of the invention, Table 700 includes a first composition and a second composition (i.e., magnesium / lidocaine) of magnesium and lidocaine, which are capable of treating mild to moderate, moderate to severe, and intractable pain at therapeutic doses with minimal side effects and a low likelihood of abuse. In contrast, taking magnesium alone is ineffective in treating any level of pain. Furthermore, lidocaine alone treats mild to moderate pain but has potential side effects such as central nervous system symptoms, seizures, and arrhythmias. Ketorheic acid can treat mild to moderate and moderate to severe pain but may cause kidney damage and bleeding as side effects. Acetaminophen (such as Tylenol) can treat mild to moderate pain, but high doses may cause liver damage. Opioids can treat mild to moderate, moderate to severe, and intractable pain but have respiratory depression and sedation as side effects and a high likelihood of abuse. Ketamine can be used to treat mild to moderate, moderate to severe, and intractable pain, but it has sedative and hallucinogenic side effects and is highly susceptible to abuse.

[0046] Figure 8 A table of compositions for treating acute psychosis and mania according to aspects of the present invention is shown. In embodiments of the invention, Table 800 includes a first composition and a second composition of magnesium and lidocaine (i.e., magnesium / lidocaine), which are capable of treating acute psychosis and mania at therapeutic doses with minimal side effects and low potential for abuse. In contrast, administration of antipsychotic drugs alone (such as haloperidol) can treat anxiety, but can cause sedation, hypotension, dizziness, and dry mouth. Furthermore, administration of benzodiazepines alone (such as Ativan, lorazepam) can treat anxiety symptoms, but has potential side effects of sedation and memory loss. Administration of atypical antipsychotic drugs (such as risperidone, clozapine) can treat acute psychosis and mania within 1-2 weeks after administration, but has several extrapyramidal symptoms, such as akathisia, dystonia, neurotic malignant syndrome, Parkinson's disease, tardive dyskinesia, and seizures. Magnesium cannot treat acute psychosis or mania. Anticonvulsants (such as valproate and carbamazepine) can treat acute psychosis and mania within 1-2 weeks of administration, but several extrapyramidal symptoms may occur, such as akathisia, dystonia, neuroleptic malignant syndrome, Parkinson's disease, tardive dyskinesia, liver failure, and thrombocytopenia. Mood stabilizers (such as lithium) can treat acute psychosis and mania within approximately 2 weeks of administration, but there are side effects such as kidney damage and toxicity risks, requiring continuous monitoring of blood levels.

[0047] In implementation schemes, computing devices, robots, or drug delivery devices may perform the processes described herein. In this case, the computing device, robot, or drug delivery device may create, maintain, deploy, support, or otherwise utilize computer infrastructure to perform the process steps of the invention for one or more patients. For example, these patients may be anyone experiencing pain, acute psychosis, or mania. Conversely, the computing device, robot, or drug delivery device may receive payments from patients under subscription and / or fee agreements, or it may receive payments from the sale of advertising content to one or more third parties.

[0048] The description of various embodiments of the present invention is for illustrative purposes only and is not intended to be exhaustive or limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terminology used herein is chosen to best explain the principles of the embodiments, their practical application, or technical improvements to technologies found in the market, or to enable those skilled in the art to understand the embodiments disclosed herein.

Claims

1. A method for treating mania, comprising: Administer at least one dose of a composition containing magnesium and lidocaine to a patient by injection; Determine whether the patient experiences a warming sensation after administering at least one dose of the composition; If the patient experiences a warm sensation, wait for the patient to indicate that the warm sensation has disappeared; and Once the patient indicated that the warming sensation had disappeared, the manic episode was verified to have decreased to the predetermined level.

2. The method according to claim 1, wherein the composition further comprises: Add 2 mg of magnesium to 50 ml of sterile water; and 200mg of preservative-free 2% lidocaine.

3. The method of claim 1, wherein administering at least one dose of the composition comprising magnesium and lidocaine to the patient further comprises: The first dose of the composition is injected into the patient; A second dose of the composition is administered to the patient. Administer a third dose of the composition to the patient; and The fourth dose of the composition was administered to the patient.

4. The method according to claim 3, wherein the first dose, the second dose, the third dose, and the fourth dose each comprise an equal amount of the composition.

5. The method according to claim 4, wherein, Waiting for the patient to indicate that the warmth has disappeared after they have expressed a feeling of warmth includes: If the patient indicates that the warming sensation has disappeared, wait for the patient to indicate that the warming sensation has disappeared after the first dose; If the patient reports that the warming sensation has disappeared, after the second dose, wait until the patient reports that the warming sensation has disappeared; and If the patient reports that the warming sensation has disappeared, wait for the patient to report that the warming sensation has disappeared after the third dose.

6. The method of claim 1, further comprising, in the absence of central nervous system (CNS) symptoms, verifying that mania has decreased to a predetermined level after administering at least one dose of the composition.

7. A method for treating pain, comprising: Administer at least one dose of a composition containing magnesium and lidocaine to a patient by injection; Determine whether the patient experiences a warming sensation after administering at least one dose of the composition; After the patient experiences a warm sensation, wait for the patient to indicate that the warm sensation has disappeared; and Once the patient reports that the warming sensation has disappeared, verify that the pain has lessened to the predetermined level.

8. The method of claim 7, wherein the composition further comprises: Add 2 mg of magnesium to 50 ml of sterile water; and 200mg of preservative-free 2% lidocaine.

9. The method of claim 7, wherein administering at least one dose of the composition comprising magnesium and lidocaine to the patient further comprises: The first dose of the composition is injected into the patient; A second dose of the composition is administered to the patient. Administer a third dose of the composition to the patient; and The fourth dose of the composition was administered to the patient.

10. The method of claim 9, wherein the first dose, the second dose, the third dose, and the fourth dose each comprise an equal amount of the composition.

11. The method according to claim 10, wherein, Determining whether the patient experiences a warming sensation after administering at least one dose of the composition also includes: Determine whether the patient experiences a warming sensation after administering the first dose of the composition; Determine whether the patient experiences a warming sensation after administering the second dose of the composition; and Determine whether the patient experiences a warming sensation after administering the third dose of the composition.

12. The method according to claim 11, wherein, Waiting for the patient to indicate that the warmth has disappeared after they have expressed a feeling of warmth includes: If the patient indicates that the warming sensation has disappeared, wait for the patient to indicate that the warming sensation has disappeared after the first dose; If the patient reports that the warming sensation has disappeared, after the second dose, wait until the patient reports that the warming sensation has disappeared; and If the patient reports that the warming sensation has disappeared, wait for the patient to report that the warming sensation has disappeared after the third dose.

13. The method according to claim 12, wherein, The process of verifying pain reduction to a predetermined level after the patient indicates that the warming sensation has disappeared includes verifying pain reduction to a predetermined level after the patient indicates that the warming sensation has disappeared after the third dose, and then injecting the patient with a fourth dose of the composition.

14. The method of claim 7, wherein the pain includes chronic intractable pain caused by an upward phenomenon.

15. The method of claim 14, wherein the predetermined level is a level at which the patient does not experience chronic intractable pain.

16. The method of claim 7, wherein the pain comprises moderate to severe pain, and the predetermined level is a level at which the patient does not experience moderate to severe pain.

17. A method for treating pain, comprising: Administer at least one dose of a composition containing magnesium and lidocaine to a patient by injection; The patient's central nervous system (CNS) symptoms are determined based on the infusion dose of the composition; In cases where the patient has CNS symptoms, the infusion dose of the composition is administered while waiting for the CNS symptoms to subside. and After the patient was free of CNS symptoms, pain was verified to have decreased to a predetermined level based on the infusion dose of the composition.

18. A method for treating mania, comprising: Infuse a patient with a specific dose of a composition containing magnesium and lidocaine; The patient's central nervous system (CNS) symptoms are determined based on the infusion dose of the composition; In cases where the patient has CNS symptoms, the infusion dose of the composition is administered while waiting for the CNS symptoms to subside. and After the patient was free of CNS symptoms, the reduction of mania to a predetermined level was verified based on the infusion dose of the composition.

19. The method of claim 18 further includes verifying that the mania has decreased to a predetermined level after the CNS symptoms have subsided.

20. The method of claim 18, wherein the CNS symptoms include at least one of tinnitus in the patient's ear and a metallic taste in the patient's mouth.

Images